AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales

Reuters

11/05

AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales

Overview

AnaptysBio Q3 collaboration revenue rises significantly due to GSK milestone achievements
Company plans to separate biopharma operations from royalty assets by YE 2026
AnaptysBio reports Q3 net income, contrasting with a loss in the prior year

Outlook

AnaptysBio plans to separate biopharma operations from royalty assets by YE 2026
Company expects $75 mln milestone from GSK's Jemperli sales in Q4 2025
AnaptysBio expects annualized Jemperli royalties of >$390 mln before 2031

Result Drivers

GSK MILESTONE - Collaboration revenue boosted by $50 mln milestone from GSK's Jemperli sales exceeding $750 mln
BIOPHARMA SEPARATION - Intent to separate biopharma operations from royalty assets by YE 2026 to unlock value
ROSNILIMAB DATA - Positive Phase 2b data for rosnilimab in rheumatoid arthritis highlighted at ACR Convergence 2025

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Collaboration Revenue		$76.32 mln
Q3 Net Income		$15.11 mln
Q3 Income From Operations		$34.70 mln
Q3 Operating Expenses		$41.61 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for AnaptysBio Inc is $62.00, about 41.9% above its November 3 closing price of $36.04

Press Release: ID:nGNX5Gv9LF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581760442"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581760442\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581760442?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 06:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581760442","market":"nz","top_or_hot":-1,"title":"AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales</title></head><body><p><span>Overview</span></p><ul><li><p>AnaptysBio Q3 collaboration revenue rises significantly due to GSK milestone achievements</p></li><li><p>Company plans to separate biopharma operations from royalty assets by YE 2026</p></li><li><p>AnaptysBio reports Q3 net income, contrasting with a loss in the prior year</p></li></ul><p><span>Outlook</span></p><ul><li><p>AnaptysBio plans to separate biopharma operations from royalty assets by YE 2026</p></li><li><p>Company expects $75 mln milestone from GSK's Jemperli sales in Q4 2025</p></li><li><p>AnaptysBio expects annualized Jemperli royalties of &gt;$390 mln before 2031</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GSK MILESTONE - Collaboration revenue boosted by $50 mln milestone from GSK's Jemperli sales exceeding $750 mln</p></li><li><p>BIOPHARMA SEPARATION - Intent to separate biopharma operations from royalty assets by YE 2026 to unlock value</p></li><li><p>ROSNILIMAB DATA - Positive Phase 2b data for rosnilimab in rheumatoid arthritis highlighted at ACR Convergence 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$76.32 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$15.11 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>$34.70 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$41.61 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for AnaptysBio Inc is $62.00, about 41.9% above its November 3 closing price of $36.04</p></li></ul><p>Press Release: <span>ID:nGNX5Gv9LF</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 06:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales</title></head><body><p><span>Overview</span></p><ul><li><p>AnaptysBio Q3 collaboration revenue rises significantly due to GSK milestone achievements</p></li><li><p>Company plans to separate biopharma operations from royalty assets by YE 2026</p></li><li><p>AnaptysBio reports Q3 net income, contrasting with a loss in the prior year</p></li></ul><p><span>Outlook</span></p><ul><li><p>AnaptysBio plans to separate biopharma operations from royalty assets by YE 2026</p></li><li><p>Company expects $75 mln milestone from GSK's Jemperli sales in Q4 2025</p></li><li><p>AnaptysBio expects annualized Jemperli royalties of &gt;$390 mln before 2031</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GSK MILESTONE - Collaboration revenue boosted by $50 mln milestone from GSK's Jemperli sales exceeding $750 mln</p></li><li><p>BIOPHARMA SEPARATION - Intent to separate biopharma operations from royalty assets by YE 2026 to unlock value</p></li><li><p>ROSNILIMAB DATA - Positive Phase 2b data for rosnilimab in rheumatoid arthritis highlighted at ACR Convergence 2025</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Collaboration Revenue</p></td><td></td><td><p>$76.32 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$15.11 mln</p></td><td></td></tr><tr><td><p>Q3 Income From Operations</p></td><td></td><td><p>$34.70 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$41.61 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for AnaptysBio Inc is $62.00, about 41.9% above its November 3 closing price of $36.04</p></li></ul><p>Press Release: <span>ID:nGNX5Gv9LF</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANAB","symbol_name":"Anaptysbio Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG1GZ:1","article_id":"2581760442","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581760442","pubTimestamp":1762294062,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AnaptysBio Q3 collaboration revenue jumps onGSK's Jemperli salesOverviewAnaptysBio Q3 collaboration revenue rises significantly due to GSK milestone achievementsCompany plans to separate biopharma ope","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANAB":"Anaptysbio Inc","BK4139":"生物科技"},"translate_title":"AnaptysBio第三季度合作收入因GSK Jemperli销售而大幅增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANAB":0.9},"content_text":"AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli salesOverviewAnaptysBio Q3 collaboration revenue rises significantly due to GSK milestone achievementsCompany plans to separate biopharma operations from royalty assets by YE 2026AnaptysBio reports Q3 net income, contrasting with a loss in the prior yearOutlookAnaptysBio plans to separate biopharma operations from royalty assets by YE 2026Company expects $75 mln milestone from GSK's Jemperli sales in Q4 2025AnaptysBio expects annualized Jemperli royalties of >$390 mln before 2031Result DriversGSK MILESTONE - Collaboration revenue boosted by $50 mln milestone from GSK's Jemperli sales exceeding $750 mlnBIOPHARMA SEPARATION - Intent to separate biopharma operations from royalty assets by YE 2026 to unlock valueROSNILIMAB DATA - Positive Phase 2b data for rosnilimab in rheumatoid arthritis highlighted at ACR Convergence 2025Key DetailsMetricBeat/MissActualConsensus EstimateQ3 Collaboration Revenue$76.32 mlnQ3 Net Income$15.11 mlnQ3 Income From Operations$34.70 mlnQ3 Operating Expenses$41.61 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 11 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for AnaptysBio Inc is $62.00, about 41.9% above its November 3 closing price of $36.04Press Release: ID:nGNX5Gv9LFFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}